References
- Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002; 360: 196–202
- Morelli A, Teboul JL, Maggiore SM, Vieillard-Baron A, Rocco M, Conti G, De Gaetano A, Picchini U, Orecchioni A, Carbone I, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: A pilot study. Crit Care Med 2006; 34: 2287–2293
- Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG, Solaro RJ. Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 1995; 77: 107–113
- Kopustinskiene DM, Pollesello P, Saris NE. Levosimendan is a mitochondrial K (ATP) channel opener. Eur J Pharmacol 2001; 428: 311–314
- Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859–1866
- Szilagyi S, Pollesello P, Levijoki J, Haikala H, Bak I, Tosaki A, Borbely A, Edes I, Papp Z. Two inotropes with different mechanisms of action: Contractile, PDE-inhibitory and direct myofibrillar effects of levosimendan and enoximone. J Cardiovasc Pharmacol 2005; 46: 369–376
- Levi M, van der Poll T. Inflammation and coagulation. Crit Care Med 2010; 38: S26–34
- Kaptan K, Erinc K, Ifran A, Yildirim V, Uzun M, Beyan C, Isik E. Levosimendan has an inhibitory effect on platelet function. Am J Hematol 2008; 83: 46–49
- Antila S, Jarvinen A, Honkanen T, Lehtonen L. Pharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin. Eur J Clin Pharmacol 2000; 56: 705–710
- Plaschke K, Bent F, Rosenhagen C, Wagner S, Hofer SJK. The inhibitory in-vitro effect of high-dose levosimendan on platelet function may be mediated through its action as a phosphodiesterase inhibitor. Coron Artery Dis 2012; 23: 215–220
- Zacharowski K, Zacharowski PA, Koch A, Baban A, Tran N, Berkels R, Papewalis C, Schulze-Osthoff K, Knuefermann P, et al. Toll-like receptor 4 plays a crucial role in the immune-adrenal response to systemic inflammatory response syndrome. Proc Nat Acad Sci USA 2006; 103: 6392–6397
- Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40: 465–471
- Antila S, Pesonen U, Lehtonen L, Tapanainen P, Nikkanen H, Vaahtera K, Scheinin H. Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators. Eur J Pharm Sci 2004; 23: 213–222
- Feuerstein G, Hallenbeck JM, Vanatta B, Rabinovici R, Perera PY, Vogel SN. Effect of gram-negative endotoxin on levels of serum corticosterone, TNF alpha, circulating blood cells, and the survival of rats. Circ Shock 1990; 30: 265–278
- Levi M. Platelets in sepsis. Hematology 2005; 10(Suppl. 1)129–131
- Levi M, Opal SM. Coagulation abnormalities in critically ill patients. Crit Care 2006; 10: 222
- Noe L, Peeters K, Izzi B, Van Geet C, Freson K. Regulators of platelet cAMP levels: Clinical and therapeutic implications. Curr Med Chem 2010; 17: 2897–2905
- Scheiermann P, Ahluwalia D, Hoegl S, Dolfen A, Revermann M, Zwissler B, Muhl H, Boost KA, Hofstetter C. Effects of intravenous and inhaled levosimendan in severe rodent sepsis. Intensive Care Med 2009; 35: 1412–1419